botulinum toxin type a

This medicine is authorised for use in the European Union.


Nuceiva is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows. It is used in adults less than 65 years of age who have moderate to severe facial lines and in whom those lines are having a significant psychological impact.

Nuceiva contains the active substance botulinum toxin type A.

This EPAR was last updated on 13/08/2020

Authorisation details

Product details
Agency product number
Active substance
Botulinum toxin type A
International non-proprietary name (INN) or common name
botulinum toxin type a
Therapeutic area (MeSH)
Skin Aging
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Evolus Pharma Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

70 Sir John Rogerson's Quay
Dublin 2

Product information

06/08/2020 Nuceiva - EMEA/H/C/004587 - IAIN/0009/G


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other muscle relaxants, peripherally acting agents

Therapeutic indication

Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.

Assessment history

How useful was this page?

Add your rating